company profile

therapeutics to improve cardiovascular health

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription. For more information about Vascepa® visit

If you are reporting an adverse event or product complaint, please email [email protected] or call the Amarin Call Center at 1-855-VASCEPA.

» See important safety information about Vascepa®
» See full prescribing information for Vascepa®

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

Who We Are

Meet the Amarin Executive Team and our Board of Directors:

» Executive Team
» Board of Directors


Alliances with complementary partners are important for maximizing our success. Amarin seeks to be the ‘partner-of-choice’ for companies that aim to develop and commercialize innovative products in the cardiovascular and synergistic therapeutic areas.

» Learn More About Partnering With Amarin

Careers @ Amarin

Amarin’s greatest assets are Vascepa® and its people. Attitude, effort and ingenuity can accomplish great things and people who exemplify these traits are the building blocks of Amarin’s success.

» View Career Opportunities



therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.

Click To Subscribe